Latest Shareholder Approvals News

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.

Tungsten Mining says non-binding debt proposals could fund up to 70% of its Watershed project, equivalent to about A$200 million against estimated pre-production capital of A$274 million. The financing remains uncommitted, with strategic investment, offtake and government-backed options still in play.

Asara Resources has emerged from FY2026 with a substantially larger Kada gold resource, strong cash backing and a more concentrated Guinea strategy. The headline resource update came after year-end and remains a Mineral Resource, not an Ore Reserve or economic mine plan.

Manhattan Gold Corporation (ASX:MHC) has emerged from a transformational year with encouraging Hook Lake drilling, expanded tenure and a sharper gold focus, but no compliant resource yet and only A$2.01 million in year-end cash. The company reported an A$8.90 million loss after absorbing exploration costs and a large loss on its lithium divestment.

Otto Energy plans to return approximately A$20 million to shareholders after consolidating its shares 100:1, with the proposed payment set at A$0.417 per post-consolidation share. The proposals require approval at the company’s 13 November 2026 AGM and remain subject to an outstanding ATO tax ruling.

Challenger Gold has locked in US$24 million through five-year unsecured convertible debentures to advance its Hualilán project, with a further US$6.3 million potentially available. The financing carries an 11% coupon and only part of the proceeds is unconditional, leaving shareholder approval and a much larger funding requirement ahead.

WhiteHawk has secured an unsecured A$1.5 million facility and says it does not currently expect to raise equity, after cutting annualised operating costs by about A$1.24 million. The funding comes at a 16% interest rate and must be repaid in full at maturity, leaving execution and cash receipts central to the plan.

Felix Group Holdings has secured A$5.54 million in institutional funding and launched a further A$1 million shareholder purchase plan as it pivots towards an open procurement platform. The ASX-listed software company is also guiding to at least 15% revenue growth in FY27.

Octava Minerals is pursuing a staged acquisition of a 400km2 fluorspar project in Argentina’s historic Sierra Grande district, backed by an approximately A$1.8 million placement. The opportunity comes with substantial verification risk: the reported grades are historical, non-JORC compliant and have not been independently validated.

ABx Group has lodged a prospectus for a fully underwritten $2 million share purchase plan, forming part of a broader $4.1 million capital raising for its Deep Leads rare earths project and ALCORE pilot plant. The offer gives eligible shareholders discounted shares and options, but leaves the final price unknown until after applications close and remains subject to shareholder approval.

Nodestream has deferred four convertible note maturities worth A$8.325 million, including a secured A$4 million note, into October and November 2027. The price of that extra time is a proposed issue of up to 189.2 million options, subject to shareholder approval.

Magnetite Mines is seeking up to A$1.5 million through a discounted share purchase plan and potential top-up placement to advance the Razorback green iron project. The raise offers free options, but also highlights the company’s continuing reliance on external funding and future strategic partners.